No Data
No Data
Express News | Viracta Therapeutics Shares Are Trading Lower After Leerink Partners Downgraded the Stock From Outperform to Market Perform and Lowered Its Price Target From $5 to $3
Express News | Viracta Therapeutics Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $3 From $5
Viracta Therapeutics Analyst Ratings
RBC Adjusts Price Target on Viracta Therapeutics to $4 From $6, Maintains Outperform
Express News | Viracta Therapeutics Inc : RBC Cuts Target Price to $4 From $6
Viracta Therapeutics | 10-Q: Q2 2024 Earnings Report